Do analysts rate SCLP or AVCT?

Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, SCLP or AVCT?

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scancell £4.71M 21.53 -£6.75M -£0.55 N/A Avacta Group £113K 2,985.44 -£30.08M -£9.66 N/A

Is SCLP or AVCT more profitable?

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -35,730.97%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Scancell -116.98% 90.29% -45.28% Avacta Group -35,730.97% -1,293.07% -21.80%

Do analysts rate SCLP or PRTC?

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 371.24%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Scancell (SCLP) Competitors

GBX 9.50 +0.15 (+1.60%)

As of 10/2/2026 12:10 PM Eastern

Compare

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

Should you buy Scancell stock or one of its competitors? Scancell's main competitors and comparable companies include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Arix Bioscience (ARIX), and Circassia Group (CIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scancell compare to Avacta Group?

Scancell (LON:SCLP) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Scancell has a beta of 0.685, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	21.53	-£6.75M	-£0.55	N/A
Avacta Group	£113K	2,985.44	-£30.08M	-£9.66	N/A

In the previous week, Avacta Group had 3 more articles in the media than Scancell. MarketBeat recorded 3 mentions for Avacta Group and 0 mentions for Scancell. Scancell's average media sentiment score of 0.00 beat Avacta Group's score of -0.24 indicating that Scancell is being referred to more favorably in the media.

Company	Overall Sentiment
Scancell	Neutral
Avacta Group	Neutral

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -35,730.97%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Avacta Group	-35,730.97%	-1,293.07%	-21.80%

1.5% of Scancell shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 13.2% of Scancell shares are owned by insiders. Comparatively, 47.7% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 37.50%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Avacta Group beats Scancell on 10 of the 16 factors compared between the two stocks.

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Scancell (LON:SCLP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

1.5% of Scancell shares are held by institutional investors. 13.2% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Scancell's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	21.53	-£6.75M	-£0.55	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Summary

Scancell beats Horizon Discovery Group plc (HZD.L) on 5 of the 8 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, PureTech Health had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Scancell. Scancell's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
PureTech Health	Neutral

PureTech Health has a net margin of 7.53% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
PureTech Health	7.53%	0.14%	-13.39%

Scancell has a beta of 0.685, indicating that its share price is 32% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its share price is 23% less volatile than the broader market.

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 371.24%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

1.5% of Scancell shares are owned by institutional investors. Comparatively, 30.7% of PureTech Health shares are owned by institutional investors. 13.2% of Scancell shares are owned by company insiders. Comparatively, 13.4% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	21.53	-£6.75M	-£0.55	N/A
PureTech Health	£6.37M	41.52	-£91.86M	-£46.00	N/A

Summary

PureTech Health beats Scancell on 12 of the 15 factors compared between the two stocks.

How does Scancell compare to Arix Bioscience?

Scancell (LON:SCLP) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Arix Bioscience has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	21.53	-£6.75M	-£0.55	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Arix Bioscience has a net margin of 105.64% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Arix Bioscience	105.64%	6.41%	2.18%

1.5% of Scancell shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 13.2% of Scancell shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scancell has a beta of 0.685, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Scancell's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Arix Bioscience	Neutral

Summary

Arix Bioscience beats Scancell on 9 of the 10 factors compared between the two stocks.

How does Scancell compare to Circassia Group?

Circassia Group (LON:CIR) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

1.5% of Scancell shares are held by institutional investors. 13.2% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Circassia Group	Neutral
Scancell	Neutral

Circassia Group has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
Scancell	£4.71M	21.53	-£6.75M	-£0.55	N/A

Circassia Group has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Circassia Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
Scancell	-116.98%	90.29%	-45.28%

Summary

Circassia Group beats Scancell on 5 of the 8 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLP vs. The Competition

Export

Metric	Scancell	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£101.44M	£3.87B	£7.14B	£2.81B
Dividend Yield	N/A	3.64%	2.53%	6.18%
P/E Ratio	-17.27	13.06	274.33	366.16
Price / Sales	21.53	1,290.02	616.11	89,437.06
Price / Cash	7.86	122.60	77.60	27.89
Price / Book	-24.37	16.63	10.93	6.83
Net Income	-£6.75M	-£22.71M	£3.51B	£5.89B
7 Day Performance	-1.45%	-2.98%	-2.02%	-0.73%
1 Month Performance	-0.94%	-10.59%	-6.17%	16.59%
1 Year Performance	-2.06%	19.46%	7.45%	23.09%

Scancell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLP Scancell	N/A	GBX 9.50 +1.6%	N/A	-0.2%	£101.44M	£4.71M	N/A	51
AVCT Avacta Group	2.0766 of 5 stars	GBX 72 flat	GBX 99 +37.5%	+15.2%	£337.36M	£113K	N/A	120	Earnings Report
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	2.7913 of 5 stars	GBX 108.79 -1.6%	GBX 508 +367.0%	-23.4%	£266.72M	£6.37M	N/A	300	News Coverage
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SCLP) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Scancell compare to Avacta Group?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Scancell compare to PureTech Health?

Summary

How does Scancell compare to Arix Bioscience?

Summary

How does Scancell compare to Circassia Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, ARIX, and CIR

How does Scancell compare to Avacta Group?

Which has more volatility and risk, SCLP or AVCT?

Which has preferable earnings and valuation, SCLP or AVCT?

Does the media prefer SCLP or AVCT?

Is SCLP or AVCT more profitable?

Do institutionals & insiders believe in SCLP or AVCT?

Do analysts rate SCLP or AVCT?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Do institutionals & insiders hold more shares of SCLP or HZD?

Does the media favor SCLP or HZD?

Is SCLP or HZD more profitable?

Which has higher earnings and valuation, SCLP or HZD?

Summary

How does Scancell compare to PureTech Health?

Does the media refer more to SCLP or PRTC?

Is SCLP or PRTC more profitable?

Which has more volatility & risk, SCLP or PRTC?

Do analysts rate SCLP or PRTC?

Do insiders and institutionals have more ownership in SCLP or PRTC?

Which has preferable valuation & earnings, SCLP or PRTC?

Summary

How does Scancell compare to Arix Bioscience?

Which has higher valuation and earnings, SCLP or ARIX?

Is SCLP or ARIX more profitable?

Do institutionals and insiders hold more shares of SCLP or ARIX?

Which has more volatility and risk, SCLP or ARIX?

Does the media prefer SCLP or ARIX?

Summary

How does Scancell compare to Circassia Group?

Do institutionals and insiders have more ownership in CIR or SCLP?

Does the media favor CIR or SCLP?

Which has stronger earnings & valuation, CIR or SCLP?

Is CIR or SCLP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools